Ombitasvir
- Generic Name
- Ombitasvir
- Brand Names
- Viekira Pak
- Drug Type
- Small Molecule
- Chemical Formula
- C50H67N7O8
- CAS Number
- 1258226-87-7
- Unique Ingredient Identifier
- 2302768XJ8
- Background
Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
When used in combination with Paritaprevir and Ritonavir (as the fixed dose product Technivie), Ombitasvir is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis .
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Chronic hepatitis C genotype 4 without cirrhosis
- Associated Therapies
- -
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 44
- Registration Number
- NCT02460133
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.